312 related articles for article (PubMed ID: 27450327)
1. Mesenchymal stem cells deliver and release conditionally replicative adenovirus depending on hepatic differentiation to eliminate hepatocellular carcinoma cells specifically.
Yuan X; Zhang Q; Li Z; Zhang X; Bao S; Fan D; Ru Y; Dong S; Zhang Y; Zhang Y; Ye Z; Xiong D
Cancer Lett; 2016 Oct; 381(1):85-95. PubMed ID: 27450327
[TBL] [Abstract][Full Text] [Related]
2. E1A-engineered human umbilical cord mesenchymal stem cells as carriers and amplifiers for adenovirus suppress hepatocarcinoma in mice.
Li Z; Ye Z; Zhang X; Zhang Q; Fan D; Zhang Y; Luo HR; Yuan X; Li Z; Xiong D
Oncotarget; 2016 Aug; 7(32):51815-51828. PubMed ID: 27322080
[TBL] [Abstract][Full Text] [Related]
3. A novel oncolytic adenovirus targeting Wnt signaling effectively inhibits cancer-stem like cell growth via metastasis, apoptosis and autophagy in HCC models.
Zhang J; Lai W; Li Q; Yu Y; Jin J; Guo W; Zhou X; Liu X; Wang Y
Biochem Biophys Res Commun; 2017 Sep; 491(2):469-477. PubMed ID: 28698142
[TBL] [Abstract][Full Text] [Related]
4. Surface expression of anti-CD3scfv stimulates locoregional immunotherapy against hepatocellular carcinoma depending on the E1A-engineered human umbilical cord mesenchymal stem cells.
Zhang Q; Yuan XF; Lu Y; Li ZZ; Bao SQ; Zhang XL; Yang YY; Fan DM; Zhang YZ; Wu CX; Guo HX; Zhang YJ; Ye Z; Xiong DS
Int J Cancer; 2017 Oct; 141(7):1445-1457. PubMed ID: 28643325
[TBL] [Abstract][Full Text] [Related]
5. Augmenting the antitumor effect of TRAIL by SOCS3 with double-regulated replicating oncolytic adenovirus in hepatocellular carcinoma.
Wei RC; Cao X; Gui JH; Zhou XM; Zhong D; Yan QL; Huang WD; Qian QJ; Zhao FL; Liu XY
Hum Gene Ther; 2011 Sep; 22(9):1109-19. PubMed ID: 21361790
[TBL] [Abstract][Full Text] [Related]
6. A hepatocellular carcinoma-specific adenovirus variant, CV890, eliminates distant human liver tumors in combination with doxorubicin.
Li Y; Yu DC; Chen Y; Amin P; Zhang H; Nguyen N; Henderson DR
Cancer Res; 2001 Sep; 61(17):6428-36. PubMed ID: 11522637
[TBL] [Abstract][Full Text] [Related]
7. Suppression of orthotopically implanted hepatocarcinoma in mice by umbilical cord-derived mesenchymal stem cells with sTRAIL gene expression driven by AFP promoter.
Yan C; Yang M; Li Z; Li S; Hu X; Fan D; Zhang Y; Wang J; Xiong D
Biomaterials; 2014 Mar; 35(9):3035-43. PubMed ID: 24406219
[TBL] [Abstract][Full Text] [Related]
8. A novel Golgi protein (GOLPH2)-regulated oncolytic adenovirus exhibits potent antitumor efficacy in hepatocellular carcinoma.
Wang Y; Liu T; Huang P; Zhao H; Zhang R; Ma B; Chen K; Huang F; Zhou X; Cui C; Liu X
Oncotarget; 2015 May; 6(15):13564-78. PubMed ID: 25980438
[TBL] [Abstract][Full Text] [Related]
9. Hepatocellular carcinoma-targeting oncolytic adenovirus overcomes hypoxic tumor microenvironment and effectively disperses through both central and peripheral tumor regions.
Yoon AR; Hong J; Kim M; Yun CO
Sci Rep; 2018 Feb; 8(1):2233. PubMed ID: 29396500
[TBL] [Abstract][Full Text] [Related]
10. Complete eradication of hepatomas using an oncolytic adenovirus containing AFP promoter controlling E1A and an E1B deletion to drive IL-24 expression.
Zhang KJ; Zhang J; Wu YM; Qian J; Liu XJ; Yan LC; Zhou XM; Xiao RJ; Wang YG; Cao X; Wei N; Liu XR; Tang B; Jiao XY; Chen K; Liu XY
Cancer Gene Ther; 2012 Sep; 19(9):619-29. PubMed ID: 22790965
[TBL] [Abstract][Full Text] [Related]
11. Systemic administration of mesenchymal stem cells loaded with a novel oncolytic adenovirus carrying a bispecific T cell engager against hepatocellular carcinoma.
Yuan X; Lu Y; Yang Y; Tian W; Fan D; Liu R; Lei X; Xia Y; Yang L; Yan S; Xiong D
Oncoimmunology; 2023; 12(1):2219544. PubMed ID: 37274296
[TBL] [Abstract][Full Text] [Related]
12. Conditionally replicative adenovirus vector carrying TRAIL gene for enhanced oncolysis of human hepatocellular carcinoma.
Ye X; Lu Q; Zhao Y; Ren Z; Ren XW; Qiu QH; Tong Y; Liang M; Hu F; Chen HZ
Int J Mol Med; 2005 Dec; 16(6):1179-84. PubMed ID: 16273304
[TBL] [Abstract][Full Text] [Related]
13. Mesenchymal Stem Cell-Mediated Delivery of an Oncolytic Adenovirus Enhances Antitumor Efficacy in Hepatocellular Carcinoma.
Yoon AR; Hong J; Li Y; Shin HC; Lee H; Kim HS; Yun CO
Cancer Res; 2019 Sep; 79(17):4503-4514. PubMed ID: 31289131
[TBL] [Abstract][Full Text] [Related]
14. Treatment of hepatocellular carcinoma by AdAFPep/rep, AdAFPep/p53, and 5-fluorouracil in mice.
Sagawa T; Yamada Y; Takahashi M; Sato Y; Kobune M; Takimoto R; Fukaura J; Iyama S; Sato T; Miyanishi K; Matsunaga T; Takayama T; Kato J; Sasaki K; Hamada H; Niitsu Y
Hepatology; 2008 Sep; 48(3):828-40. PubMed ID: 18756484
[TBL] [Abstract][Full Text] [Related]
15. Use of microRNA Let-7 to control the replication specificity of oncolytic adenovirus in hepatocellular carcinoma cells.
Jin H; Lv S; Yang J; Wang X; Hu H; Su C; Zhou C; Li J; Huang Y; Li L; Liu X; Wu M; Qian Q
PLoS One; 2011; 6(7):e21307. PubMed ID: 21814544
[TBL] [Abstract][Full Text] [Related]
16. A hypoxia- and {alpha}-fetoprotein-dependent oncolytic adenovirus exhibits specific killing of hepatocellular carcinomas.
Kwon OJ; Kim PH; Huyn S; Wu L; Kim M; Yun CO
Clin Cancer Res; 2010 Dec; 16(24):6071-82. PubMed ID: 21169258
[TBL] [Abstract][Full Text] [Related]
17. A novel A33 promoter-based conditionally replicative adenovirus suppresses tumor growth and eradicates hepatic metastases in human colon cancer models.
Cafferata EG; Macció DR; Lopez MV; Viale DL; Carbone C; Mazzolini G; Podhajcer OL
Clin Cancer Res; 2009 May; 15(9):3037-49. PubMed ID: 19336523
[TBL] [Abstract][Full Text] [Related]
18. Increased safety with preserved antitumoral efficacy on hepatocellular carcinoma with dual-regulated oncolytic adenovirus.
Zhang Q; Chen G; Peng L; Wang X; Yang Y; Liu C; Shi W; Su C; Wu H; Liu X; Wu M; Qian Q
Clin Cancer Res; 2006 Nov; 12(21):6523-31. PubMed ID: 17085667
[TBL] [Abstract][Full Text] [Related]
19. Anti-tumor activity of a miR-199-dependent oncolytic adenovirus.
Callegari E; Elamin BK; D'Abundo L; Falzoni S; Donvito G; Moshiri F; Milazzo M; Altavilla G; Giacomelli L; Fornari F; Hemminki A; Di Virgilio F; Gramantieri L; Negrini M; Sabbioni S
PLoS One; 2013; 8(9):e73964. PubMed ID: 24069256
[TBL] [Abstract][Full Text] [Related]
20. Transthyretin-driven oncolytic adenovirus suppresses tumor growth in orthotopic and ascites models of hepatocellular carcinoma.
Hsieh JL; Lee CH; Teo ML; Lin YJ; Huang YS; Wu CL; Shiau AL
Cancer Sci; 2009 Mar; 100(3):537-45. PubMed ID: 19134007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]